- Click here for full review (subscribers only).
Abstract
- Trials of single-agent therapy with
artemisinin derivatives showed rapid
clinical and parasitological effects,
but relapses were frequent during
the weeks following treatment.
Artemisinin derivatives are therefore
used in combination with other antimalarials.
- In 2006, no parasite resistance to
artemisinin derivatives has been
detected in Southeast Asia after about
10 years of use.
- In Southeast Asia, parasitological
failure at 28 days was less frequent
after treatment with artesunate (for
3 days) plus mefloquine than with
mefloquine alone. The artemether +
lumefantrine combination has similar
efficacy to the artesunate + mefloquine
combination.
- In Africa, several
trials have shown that combinations
based on artemisinin derivatives are
more consistently effective than combinations
not including artemisinin derivatives. In regions with high-level
resistance to amodiaquine, one trial
showed that artemether + lumefantrine
was more effective than artesunate
+ amodiaquine.
- The main adverse effects of
artemisinin derivatives are gastrointestinal
and neurological disorders,
but these are rarely severe. Combinations
based on artemisinin derivatives
have different adverse effects, depending
on the drugs used.
Artesunate is the artemisinin derivative
most widely studied in pregnant
women: in a series of more than
400 pregnancies, abnormalities were
no more frequent than in the general
population.
- In practice, in regions where P. falciparum
malaria is endemic, early
combination therapy based on
artemisinin derivatives is often recommended.
For uncomplicated
malaria in travellers, combination
therapy based on artemisinin derivatives
is one option, along with atovaquone
+ proguanil, quinine (less convenient)
and mefloquine (frequent
neuropsychological effects).
©Prescrire August 2008
Source: Prescrire International 2008; 16 (96): 162-168.
- Click here for full review (subscribers only).
- More articles in Prescrire's "Spotlight"...